S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
NASDAQ:OMIC

Singular Genomics Systems Stock Forecast, Price & News

$11.81
-0.56 (-4.53 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.70
$12.69
50-Day Range
$11.81
$20.10
52-Week Range
$11.70
$33.37
Volume73,756 shs
Average Volume191,330 shs
Market Capitalization$845.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OMIC News and Ratings via Email

Sign-up to receive the latest news and ratings for Singular Genomics Systems and its competitors with MarketBeat's FREE daily newsletter.


About Singular Genomics Systems

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.

Headlines

Singular Genomics Systems (NASDAQ:OMIC) Hits New 52-Week Low at $11.70
Singular Genomics Systems (NASDAQ:OMIC) Hits New 52-Week Low at $11.70
September 24, 2021 |  americanbankingnews.com
Singular Genomics Systems (NASDAQ:OMIC)  Shares Down 4%
Singular Genomics Systems (NASDAQ:OMIC) Shares Down 4%
September 21, 2021 |  americanbankingnews.com
Singular Genomics Systems (NASDAQ:OMIC) Hits New 1-Year Low at $13.15
Singular Genomics Systems (NASDAQ:OMIC) Hits New 1-Year Low at $13.15
September 17, 2021 |  americanbankingnews.com
Singular Genomics Systems (NASDAQ:OMIC) Trading Down 5.8%
Singular Genomics Systems (NASDAQ:OMIC) Trading Down 5.8%
September 15, 2021 |  americanbankingnews.com
Singular Genomics Systems (NASDAQ:OMIC) Shares Gap Down to $16.91
Singular Genomics Systems (NASDAQ:OMIC) Shares Gap Down to $16.91
September 13, 2021 |  americanbankingnews.com
Singular Genomics Systems (NASDAQ:OMIC)  Shares Down 3.3%
Singular Genomics Systems (NASDAQ:OMIC) Shares Down 3.3%
September 7, 2021 |  americanbankingnews.com
Singular Genomics Systems (NASDAQ:OMIC) Shares Gap Down to $16.64
Singular Genomics Systems (NASDAQ:OMIC) Shares Gap Down to $16.64
September 1, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

933rd out of 1,351 stocks

Analytical Instruments Industry

22nd out of 30 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Singular Genomics Systems (NASDAQ:OMIC) Frequently Asked Questions

Is Singular Genomics Systems a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Singular Genomics Systems stock.
View analyst ratings for Singular Genomics Systems
or view top-rated stocks.

What stocks does MarketBeat like better than Singular Genomics Systems?

Wall Street analysts have given Singular Genomics Systems a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Singular Genomics Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Singular Genomics Systems' next earnings date?

Singular Genomics Systems is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Singular Genomics Systems
.

How were Singular Genomics Systems' earnings last quarter?

Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced its earnings results on Tuesday, August, 3rd. The company reported ($0.43) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.22.
View Singular Genomics Systems' earnings history
.

What price target have analysts set for OMIC?

4 brokers have issued twelve-month target prices for Singular Genomics Systems' shares. Their forecasts range from $26.00 to $35.00. On average, they expect Singular Genomics Systems' share price to reach $30.33 in the next twelve months. This suggests a possible upside of 156.8% from the stock's current price.
View analysts' price targets for Singular Genomics Systems
or view top-rated stocks among Wall Street analysts.

Who are Singular Genomics Systems' key executives?

Singular Genomics Systems' management team includes the following people:
  • Mr. Andrew Spaventa, Founder, CEO & Chairperson of the Board (Age 36)
  • Mr. David J. Daly, Pres & COO (Age 59)
  • Dr. Eli N. Glezer Ph.D., Founder & Chief Scientific Officer (Age 52)
  • Mr. Dalen Meeter, Sr. VP of Fin. (Age 43)
  • Ms. Daralyn Durie, Gen. Counsel (Age 53)
  • Mr. Jorge Velarde Jr., Sr. VP of Corp. Devel. & Strategy (Age 54)
  • Mr. Scott Thomas, Sr. VP of Sales & Marketing
  • Mr. Vincent Brancaccio, Head of HR (Age 38)

When did Singular Genomics Systems IPO?

(OMIC) raised $178 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank served as the underwriters for the IPO.

What is Singular Genomics Systems' stock symbol?

Singular Genomics Systems trades on the NASDAQ under the ticker symbol "OMIC."

When does the company's lock-up period expire?

Singular Genomics Systems' lock-up period expires on Tuesday, November 23rd. Singular Genomics Systems had issued 10,200,000 shares in its public offering on May 27th. The total size of the offering was $224,400,000 based on an initial share price of $22.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who are Singular Genomics Systems' major shareholders?

Singular Genomics Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (4.31%), Perceptive Advisors LLC (4.31%), FMR LLC (2.96%), Coatue Management LLC (2.96%), Goldman Sachs Group Inc. (1.37%) and Vanguard Group Inc. (1.06%). Company insiders that own Singular Genomics Systems stock include James E Flynn and Sheryl L Conley.

Which major investors are buying Singular Genomics Systems stock?

OMIC stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, FMR LLC, Coatue Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., Nicholas Investment Partners LP, and UBS Asset Management Americas Inc..

How do I buy shares of Singular Genomics Systems?

Shares of OMIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Singular Genomics Systems' stock price today?

One share of OMIC stock can currently be purchased for approximately $11.81.

How much money does Singular Genomics Systems make?

Singular Genomics Systems has a market capitalization of $845.08 million.

How many employees does Singular Genomics Systems have?

Singular Genomics Systems employs 138 workers across the globe.

What is Singular Genomics Systems' official website?

The official website for Singular Genomics Systems is singulargenomics.com.

Where are Singular Genomics Systems' headquarters?

Singular Genomics Systems is headquartered at 10931 N. TORREY PINES ROAD SUITE 100, LA JOLLA CA, 92037.

How can I contact Singular Genomics Systems?

Singular Genomics Systems' mailing address is 10931 N. TORREY PINES ROAD SUITE 100, LA JOLLA CA, 92037. The company can be reached via phone at 858-333-7830.


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.